Novo Nordisk is doubling down on its collaboration ... focus to cover Novo’s defining indications—obesity and Type 2 diabetes—and increases the program cap to 20. If the programs hit their ...
Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted ...
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback